Improved CAR-T cell targeting of cancer
Bidragets beskrivning
Chimeric antigen receptor (CAR)-T cell therapy is a promising new approach for treating cancer, where an engineered CAR molecule is introduced into patient's immune cells to direct them to destroy cancer cells. CAR-T cell therapy has been very successful in treating leukemias and lymphomas. However, most cancers lack any truly cancer-specific determinants, and it has been difficult to create CAR-T cells that would efficiently kill cancer without attacking healthy tissues. Our laboratory has developed a new and highly tunable targeting technology based on a small protein module, known as the SH3 domain. We have already shown that using modified SH3 domains it is possible to create CAR-T cells that can sense even relative differences between cancer and normal cell surface structures. Here we propose a series of experiments designed to exploit this opportunity in order to develop potent but safe CAR-T cell therapies for ovarian and other cancers that have remained difficult to treat.
Visa merStartår
2020
Slutår
2024
Beviljade finansiering
Övriga uppgifter
Finansieringsbeslutets nummer
331787
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet
Identifierade teman
cancer